Developer docs
API playgroundTry for free, no card

Search company profiles

Bellbrook Labs

Full company profile

uuid000b5qk

Namestring
Bellbrook Labs
Legal namestring
BellBrook Labs
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Bellbrook Labs is a privately held biochemical assay company founded in 2005 and headquartered in Madison, Wisconsin. The company develops and sells high-throughput screening (HTS) assay platforms used by pharmaceutical, biotechnology, academic, and contract research organizations for enzyme-targeted drug discovery. Its technology portfolio centers on direct nucleotide detection via the Transcreener platform — covering kinases, ATPases, GTPases, phosphodiesterases, glycosyltransferases, and exonucleases — and is extended through AptaFluor methyltransferase assays, Heliscreener helicase assays, the Enzolution complete assay systems, and a catalog of HTS-ready recombinant human enzymes.

Bellbrook Labs monetizes through three channels: (1) catalog sales of assay kits and recombinant enzymes via direct e-commerce, an inside sales team, and an international distributor network; (2) fee-for-service scientific offerings including assay development, hit validation, ATPase/cGAS-STING/GTPase/helicase profiling, and lead discovery; and (3) free evaluation kits and a webinar/conference-driven content marketing motion. The mix-and-read, direct-detection format is positioned as a robust, low-interference alternative to luciferase-coupled assays, with validated performance in 384- and 1536-well automated formats.

The company operates with 11-50 employees, is founder-led (Robert Lowery serves as co-founder, president, and CEO), and shows no institutional venture capital backing in its disclosed funding record — only a 2012 round and a 2017 NIH NIGMS SBIR Phase I grant of $288,000. Recent strategic activity includes a February 2026 co-development partnership with SPT Labtech to launch a miniaturized VPS4B ATPase inhibitor screening platform, followed by a May 2026 extension into sirtuin (epigenetic) drug discovery via the Transcreener OAADPr SIRT Assay.

Short descriptiontext

Bellbrook Labs is a privately held Madison, Wisconsin-based biochemical assay company founded in 2005 that develops and sells Transcreener, AptaFluor, Heliscreener, and Enzolution high-throughput screening assay kits, recombinant enzymes, and contract profiling services for enzyme-targeted drug discovery by pharmaceutical, biotech, academic, and CRO customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMadison, United States
HQ citystring
Madison
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biochemical assay kits, high-throughput screening, drug discovery reagents, enzyme assay platforms, recombinant enzymes
Industry4 codes
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAFAK
Bioanalytical & Biomarker Assays (Preclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Biochemical Assay Kits
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Assay Kits and Reagents
TypeOne Time License
Description

Sale of biochemical HTS assay kits including Transcreener, AptaFluor, and Heliscreener platforms. Includes kinase assay kits, ATPase assay kits, methyltransferase assay kits, and specialty enzyme assays.

bellbrooklabs.com
2Recombinant Enzymes
TypeOne Time License
Description

Sale of purified, active human enzymes validated in BellBrook's assays. Products include VPS4A, VPS4B, WRN Helicase, DDX helicases, cGAS, TREX1, PARG, and other disease-relevant enzymes.

bellbrooklabs.com
3Scientific Services
TypeProfessional Services
Description

Fee-for-service assay development, compound testing, dose-response studies, hit validation, and profiling services. Services include Assay Development Services, Lead Discovery Services, ATPase Profiling Services, cGAS/STING Profiling Services, GTPase Profiling Services, Helicase Profiling Services, and Thermal Shift Assay Services.

bellbrooklabs.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Assay kits and reagents - quote-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

No public pricing listed; requires quote request. Next-day delivery available for domestic orders.

bellbrooklabs.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Transcreener
Description

HTS platform for direct detection of nucleotides produced by nucleotide-dependent enzymatic activity including kinases, ATPases, GTPases, phosphodiesterases, glycosyltransferases, and exonucleases.

bellbrooklabs.com
+3 more records
Core offering1 text field

Bellbrook Labs develops, manufactures, and sells biochemical high-throughput screening (HTS) assay kits, recombinant enzymes, assay plates, and small-molecule inhibitors, alongside contract assay development and target profiling services. Its core platforms — Transcreener, AptaFluor, Heliscreener, and Enzolution — enable direct, mix-and-read detection of enzymatic activity for kinase, ATPase, GTPase, phosphodiesterase, glycosyltransferase, exonuclease, methyltransferase, and helicase targets in drug discovery workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Z' > 0.7 demonstrated in SIRT1 and SIRT2 assays with Transcreener OAADPr assay
+2 more records
Product overview1 text field

Bellbrook Labs provides a comprehensive portfolio of biochemical high-throughput screening (HTS) assay solutions for drug discovery. The core offering centers on three proprietary technology platforms: Transcreener (direct nucleotide detection for kinases, ATPases, GTPases, phosphodiesterases, and other nucleotide-consuming enzymes), AptaFluor (SAH methyltransferase detection), and Heliscreener (RNA/DNA helicase unwinding assays). These platforms are complemented by the Enzolution brand of complete assay systems combining validated enzymes, substrates, and protocols. Bellbrook also offers a catalog of HTS-ready recombinant human enzymes and a suite of contract assay development and profiling services. The product architecture enables customers to run proven assays in their own labs or collaborate with Bellbrook scientists for assay validation, hit discovery, and CRO transfer. The company positions its technology as robust, mix-and-read solutions designed for automated HTS environments on common multimode readers.

Product and service14 records
1Transcreener HTS Assays
CategoryBiochemical HTS assay kits
Description

Flagship HTS assay platform for direct detection of nucleotides produced by enzymes, available in fluorescence polarization (FP), fluorescence intensity (FI), and TR-FRET detection modes with continuous or endpoint options. Sold as a family of kits (ADP² kinase, GDP GTPase, pADPr PARP, cGAMP cGAS, OAADPr SIRT, ADPR, ADO CD73, AMP/GMP phosphodiesterase, EPIGEN SAH, dAMP exonuclease, UDP glycosyltransferase, 2-5A OAS) for drug discovery scientists running biochemical HTS campaigns.

2AptaFluor SAH Methyltransferase Assay Kits
CategoryBiochemical HTS assay kits
Description

Mix-and-read assay kits for detecting S-adenosylhomocysteine (SAH) produced by methyltransferases, enabling inhibitor screening against any methyltransferase using SAM at Km concentration. Targeted at epigenetic drug discovery researchers.

3Heliscreener Helicase Unwinding Assay Kits
CategoryBiochemical HTS assay kits
Description

Assay kits for measuring RNA and DNA helicase unwinding activity, including dedicated kits for RNA helicases, BLM (Bloom syndrome protein) helicase, and WRN (Werner syndrome helicase). Sold to drug discovery researchers working on helicase targets.

4Enzolution Assay Systems
CategoryComplete assay systems
Description

Bundle product line that packages validated recombinant enzymes, substrates, detection reagents, buffers, and protocols into ready-to-run assay systems for inhibitor discovery against specific enzyme targets. Designed to be used with the Transcreener and AptaFluor detection platforms and sold to HTS and screening groups.

5HTS-Ready Recombinant Enzymes
CategoryRecombinant enzymes
Description

Catalog of purified, active recombinant human enzymes validated for high-throughput screening, sold individually as standalone reagents for customers who want to assemble their own assay workflows with Bellbrook detection reagents. Includes targets such as cGAS, TREX1, PolQ, WRN, PARG, CD38, DDX helicases, MDA5, RIG-I, VPS4A, VPS4B, and more.

6HTS Assay Plates
CategoryAssay consumables
Description

Microplates optimized for use in high-throughput screening workflows with Bellbrook assay kits, sold as a supporting consumable for automated screening platforms.

7Reference Inhibitors
CategoryReference inhibitors
Description

Small set of reference small-molecule inhibitors for SMARCA2/4, TBK1, SIRT1, DDX1/DDX41, and PARP1/PARP2 targets, sold as tool compounds for customers running control experiments with Bellbrook assays.

8Assay Development Services
CategoryContract research services
Description

Custom assay development service in which Bellbrook scientists establish, troubleshoot, and validate biochemical workflows for customer targets, with the goal of enabling in-house screening, hit confirmation, or transfer to a CRO. Targeted at pharmaceutical and biotech drug discovery teams.

9Lead Discovery Services
CategoryContract research services
Description

Compound testing, dose-response studies, hit validation, and profiling services that help customers progress hits from primary screens into qualified lead matter, positioned for AI-driven hit triage workflows. Served to pharmaceutical and biotech discovery teams.

10ATPase Profiling Services
CategoryContract research services
Description

Contract profiling service for ATPase enzyme targets using BellBrook's Transcreener ADP2 detection platform, delivered to pharmaceutical and biotech customers for compound screening and characterization.

11cGAS/STING Profiling Services
CategoryContract research services
Description

Contract profiling service targeting cGAS and STING pathway enzymes for customers developing innate immunity and oncology drug discovery programs, supported by Bellbrook's Transcreener cGAMP cGAS detection reagents.

12GTPase Profiling Services
CategoryContract research services
Description

Contract profiling service for GTPase enzyme targets using Bellbrook's Transcreener GDP GTPase detection chemistry, sold to drug discovery teams screening GTPase inhibitors.

13Helicase Profiling Services
14Thermal Shift Assay Services
CategoryContract research services
Description

Thermal shift (DSF) profiling service for measuring compound-target interactions through changes in protein thermal stability, sold to drug discovery teams supporting hit triage and binding characterization.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Collaboration announced at SLAS 2026 to develop a miniaturized, high-throughput cell-based assay for discovering VPS4B ATPase inhibitors. The platform combines BellBrook Labs' Transcreener ADP2 fluorescence polarization assay with SPT Labtech's dragonfly automated dispensing system, operating in 384- and 1536-well formats. Successfully identified 13 novel VPS4B inhibitors as proof of concept.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bio-Rad supplies life-science research reagents, antibodies, and assay kits used in drug discovery workflows. Overlaps with BellBrook in biochemical reagents and recombinant proteins but with a much broader catalog.

TypeEmerging player
Description

Enzo Life Sciences offers assay kits, recombinant proteins, and biochemical reagents for life-science research with overlap to BellBrook in enzyme and signaling-pathway assays. Smaller and broader-specialty compared to BellBrook's HTS focus.

TypeRegional player
Description

Charles River provides discovery and safety assessment services including biochemical assay support for pharma clients. Comparable to BellBrook on the contract profiling services side, though with a much broader non-clinical CRO footprint.

TypeBroad incumbent
Description

Promega is a large, diversified life-science tools company offering biochemical and cell-based assay reagents including kinase and ATPase assays. Overlaps with BellBrook's biochemical assay kits but with a much broader product portfolio and global commercial reach.

TypeDirect peer
Description

BPS Biosciences develops recombinant enzymes and biochemical assay kits for drug discovery, including kinase, epigenetic, and immunology targets. Directly comparable to BellBrook's enzyme catalog and biochemical HTS assay portfolio.

TypeBroad incumbent
Description

Thermo Fisher offers an extensive life-science reagents catalog including biochemical assay kits, recombinant enzymes, and HTS consumables. Competes broadly across nearly every BellBrook product line as part of a much larger portfolio.

TypeDirect peer
Description

Eurofins DiscoverX provides biochemical and cell-based assay kits, profiling services, and recombinant cell lines for HTS drug discovery. Overlaps with BellBrook in biochemical enzyme assays and contract screening services.

TypeBroad incumbent
Description

Revvity provides HTS detection reagents, plate readers, automation, and screening services across biochemical and cell-based modalities. Competes with BellBrook at the assay-reagent layer while also offering the instrument and software stack BellBrook does not.

TypeDirect peer
Description

Reaction Biology offers biochemical profiling services and assay reagents covering kinases, ATPases, and other enzyme targets. Closely matches BellBrook's combined products-and-services business model in biochemical HTS.

TypeBroad incumbent
Description

Cisbio's HTRF (Homogeneous Time-Resolved Fluorescence) technology is a widely adopted TR-FRET-based detection platform for HTS. Represents the incumbent alternative to BellBrook's Transcreener FP/TR-FRET assays for kinase and other enzyme targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bellbrook Labs

Drug Discovery Biochemical Assay Kitsbellbrooklabs.com

Bellbrook Labs is a privately held Madison, Wisconsin-based biochemical assay company founded in 2005 that develops and sells Transcreener, AptaFluor, Heliscreener, and Enzolution high-throughput screening assay kits, recombinant enzymes, and contract profiling services for enzyme-targeted drug discovery by pharmaceutical, biotech, academic, and CRO customers.

What Bellbrook Labs does

Bellbrook Labs is a privately held biochemical assay company founded in 2005 and headquartered in Madison, Wisconsin. The company develops and sells high-throughput screening (HTS) assay platforms used by pharmaceutical, biotechnology, academic, and contract research organizations for enzyme-targeted drug discovery. Its technology portfolio centers on direct nucleotide detection via the Transcreener platform — covering kinases, ATPases, GTPases, phosphodiesterases, glycosyltransferases, and exonucleases — and is extended through AptaFluor methyltransferase assays, Heliscreener helicase assays, the Enzolution complete assay systems, and a catalog of HTS-ready recombinant human enzymes.

Bellbrook Labs monetizes through three channels: (1) catalog sales of assay kits and recombinant enzymes via direct e-commerce, an inside sales team, and an international distributor network; (2) fee-for-service scientific offerings including assay development, hit validation, ATPase/cGAS-STING/GTPase/helicase profiling, and lead discovery; and (3) free evaluation kits and a webinar/conference-driven content marketing motion. The mix-and-read, direct-detection format is positioned as a robust, low-interference alternative to luciferase-coupled assays, with validated performance in 384- and 1536-well automated formats.

The company operates with 11-50 employees, is founder-led (Robert Lowery serves as co-founder, president, and CEO), and shows no institutional venture capital backing in its disclosed funding record — only a 2012 round and a 2017 NIH NIGMS SBIR Phase I grant of $288,000. Recent strategic activity includes a February 2026 co-development partnership with SPT Labtech to launch a miniaturized VPS4B ATPase inhibitor screening platform, followed by a May 2026 extension into sirtuin (epigenetic) drug discovery via the Transcreener OAADPr SIRT Assay.

Bellbrook Labs firmographics

Firmographics
Name
Bellbrook Labs
Legal name
BellBrook Labs
Website
https://bellbrooklabs.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Bellbrook Labs is a privately held Madison, Wisconsin-based biochemical assay company founded in 2005 that develops and sells Transcreener, AptaFluor, Heliscreener, and Enzolution high-throughput screening assay kits, recombinant enzymes, and contract profiling services for enzyme-targeted drug discovery by pharmaceutical, biotech, academic, and CRO customers.
Ownership category
akta.pro rank

Bellbrook Labs industry classification

Industry
Product category
Drug Discovery Biochemical Assay Kits
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAFAK
Bioanalytical & Biomarker Assays (Preclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Biochemical assay kits
  • High-throughput screening
  • Drug discovery reagents
  • Enzyme assay platforms
  • Recombinant enzymes

Where Bellbrook Labs is headquartered

Location

Headquarters

HQ city
Madison
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bellbrook Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Assay Kits and Reagents: Sale of biochemical HTS assay kits including Transcreener, AptaFluor, and Heliscreener platforms. Includes kinase assay kits, ATPase assay kits, methyltransferase assay kits, and specialty enzyme assays.
  2. Recombinant Enzymes: Sale of purified, active human enzymes validated in BellBrook's assays. Products include VPS4A, VPS4B, WRN Helicase, DDX helicases, cGAS, TREX1, PARG, and other disease-relevant enzymes.
  3. Scientific Services: Fee-for-service assay development, compound testing, dose-response studies, hit validation, and profiling services. Services include Assay Development Services, Lead Discovery Services, ATPase Profiling Services, cGAS/STING Profiling Services, GTPase Profiling Services, Helicase Profiling Services, and Thermal Shift Assay Services.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAssay kits and reagents - quote-based pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Bellbrook Labs product offering

Product offering

Core offering

Bellbrook Labs develops, manufactures, and sells biochemical high-throughput screening (HTS) assay kits, recombinant enzymes, assay plates, and small-molecule inhibitors, alongside contract assay development and target profiling services. Its core platforms — Transcreener, AptaFluor, Heliscreener, and Enzolution — enable direct, mix-and-read detection of enzymatic activity for kinase, ATPase, GTPase, phosphodiesterase, glycosyltransferase, exonuclease, methyltransferase, and helicase targets in drug discovery workflows.

Product overview

Bellbrook Labs provides a comprehensive portfolio of biochemical high-throughput screening (HTS) assay solutions for drug discovery. The core offering centers on three proprietary technology platforms: Transcreener (direct nucleotide detection for kinases, ATPases, GTPases, phosphodiesterases, and other nucleotide-consuming enzymes), AptaFluor (SAH methyltransferase detection), and Heliscreener (RNA/DNA helicase unwinding assays). These platforms are complemented by the Enzolution brand of complete assay systems combining validated enzymes, substrates, and protocols. Bellbrook also offers a catalog of HTS-ready recombinant human enzymes and a suite of contract assay development and profiling services. The product architecture enables customers to run proven assays in their own labs or collaborate with Bellbrook scientists for assay validation, hit discovery, and CRO transfer. The company positions its technology as robust, mix-and-read solutions designed for automated HTS environments on common multimode readers.

Differentiator

Problem solved

Functional benefit

Brands

  • Transcreener: HTS platform for direct detection of nucleotides produced by nucleotide-dependent enzymatic activity including kinases, ATPases, GTPases, phosphodiesterases, glycosyltransferases, and exonucleases.
  • AptaFluor
  • Heliscreener
  • Enzolution

Products and services

  • Transcreener HTS Assays Flagship HTS assay platform for direct detection of nucleotides produced by enzymes, available in fluorescence polarization (FP), fluorescence intensity (FI), and TR-FRET detection modes with continuous or endpoint options. Sold as a family of kits (ADP² kinase, GDP GTPase, pADPr PARP, cGAMP cGAS, OAADPr SIRT, ADPR, ADO CD73, AMP/GMP phosphodiesterase, EPIGEN SAH, dAMP exonuclease, UDP glycosyltransferase, 2-5A OAS) for drug discovery scientists running biochemical HTS campaigns.
  • AptaFluor SAH Methyltransferase Assay Kits Mix-and-read assay kits for detecting S-adenosylhomocysteine (SAH) produced by methyltransferases, enabling inhibitor screening against any methyltransferase using SAM at Km concentration. Targeted at epigenetic drug discovery researchers.
  • Heliscreener Helicase Unwinding Assay Kits Assay kits for measuring RNA and DNA helicase unwinding activity, including dedicated kits for RNA helicases, BLM (Bloom syndrome protein) helicase, and WRN (Werner syndrome helicase). Sold to drug discovery researchers working on helicase targets.
  • Enzolution Assay Systems Bundle product line that packages validated recombinant enzymes, substrates, detection reagents, buffers, and protocols into ready-to-run assay systems for inhibitor discovery against specific enzyme targets. Designed to be used with the Transcreener and AptaFluor detection platforms and sold to HTS and screening groups.
  • HTS-Ready Recombinant Enzymes Catalog of purified, active recombinant human enzymes validated for high-throughput screening, sold individually as standalone reagents for customers who want to assemble their own assay workflows with Bellbrook detection reagents. Includes targets such as cGAS, TREX1, PolQ, WRN, PARG, CD38, DDX helicases, MDA5, RIG-I, VPS4A, VPS4B, and more.
  • HTS Assay Plates Microplates optimized for use in high-throughput screening workflows with Bellbrook assay kits, sold as a supporting consumable for automated screening platforms.
  • Reference Inhibitors Small set of reference small-molecule inhibitors for SMARCA2/4, TBK1, SIRT1, DDX1/DDX41, and PARP1/PARP2 targets, sold as tool compounds for customers running control experiments with Bellbrook assays.
  • Assay Development Services Custom assay development service in which Bellbrook scientists establish, troubleshoot, and validate biochemical workflows for customer targets, with the goal of enabling in-house screening, hit confirmation, or transfer to a CRO. Targeted at pharmaceutical and biotech drug discovery teams.
  • Lead Discovery Services Compound testing, dose-response studies, hit validation, and profiling services that help customers progress hits from primary screens into qualified lead matter, positioned for AI-driven hit triage workflows. Served to pharmaceutical and biotech discovery teams.
  • ATPase Profiling Services Contract profiling service for ATPase enzyme targets using BellBrook's Transcreener ADP2 detection platform, delivered to pharmaceutical and biotech customers for compound screening and characterization.
  • cGAS/STING Profiling Services Contract profiling service targeting cGAS and STING pathway enzymes for customers developing innate immunity and oncology drug discovery programs, supported by Bellbrook's Transcreener cGAMP cGAS detection reagents.
  • GTPase Profiling Services Contract profiling service for GTPase enzyme targets using Bellbrook's Transcreener GDP GTPase detection chemistry, sold to drug discovery teams screening GTPase inhibitors.
  • Helicase Profiling Services
  • Thermal Shift Assay Services Thermal shift (DSF) profiling service for measuring compound-target interactions through changes in protein thermal stability, sold to drug discovery teams supporting hit triage and binding characterization.

Quantifiable outcome

  • Z' > 0.7 demonstrated in SIRT1 and SIRT2 assays with Transcreener OAADPr assay
  • +2 more outcomes

Companies that use Bellbrook Labs

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Bellbrook Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bellbrook Labs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SPT LabtechcoreStrategic or Co-development Partner · 1 February 2026Collaboration announced at SLAS 2026 to develop a miniaturized, high-throughput cell-based assay for discovering VPS4B ATPase inhibitors. The platform combines BellBrook Labs' Transcreener ADP2 fluorescence polarization assay with SPT Labtech's dragonfly automated dispensing system, operating in 384- and 1536-well formats. Successfully identified 13 novel VPS4B inhibitors as proof of concept.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Bellbrook Labs competitors and assessment

Company assessment

Broad incumbents

  • Bio-Rad Laboratories: Bio-Rad supplies life-science research reagents, antibodies, and assay kits used in drug discovery workflows. Overlaps with BellBrook in biochemical reagents and recombinant proteins but with a much broader catalog.
  • Promega Corporation: Promega is a large, diversified life-science tools company offering biochemical and cell-based assay reagents including kinase and ATPase assays. Overlaps with BellBrook's biochemical assay kits but with a much broader product portfolio and global commercial reach.
  • Thermo Fisher Scientific: Thermo Fisher offers an extensive life-science reagents catalog including biochemical assay kits, recombinant enzymes, and HTS consumables. Competes broadly across nearly every BellBrook product line as part of a much larger portfolio.
  • Revvity (formerly PerkinElmer Life Sciences): Revvity provides HTS detection reagents, plate readers, automation, and screening services across biochemical and cell-based modalities. Competes with BellBrook at the assay-reagent layer while also offering the instrument and software stack BellBrook does not.
  • Cisbio / PerkinElmer HTRF (now Revvity): Cisbio's HTRF (Homogeneous Time-Resolved Fluorescence) technology is a widely adopted TR-FRET-based detection platform for HTS. Represents the incumbent alternative to BellBrook's Transcreener FP/TR-FRET assays for kinase and other enzyme targets.

Emerging players

  • Enzo Life Sciences: Enzo Life Sciences offers assay kits, recombinant proteins, and biochemical reagents for life-science research with overlap to BellBrook in enzyme and signaling-pathway assays. Smaller and broader-specialty compared to BellBrook's HTS focus.

Regional players

  • Charles River Laboratories: Charles River provides discovery and safety assessment services including biochemical assay support for pharma clients. Comparable to BellBrook on the contract profiling services side, though with a much broader non-clinical CRO footprint.

Direct peers

  • BPS Biosciences: BPS Biosciences develops recombinant enzymes and biochemical assay kits for drug discovery, including kinase, epigenetic, and immunology targets. Directly comparable to BellBrook's enzyme catalog and biochemical HTS assay portfolio.
  • Eurofins DiscoverX: Eurofins DiscoverX provides biochemical and cell-based assay kits, profiling services, and recombinant cell lines for HTS drug discovery. Overlaps with BellBrook in biochemical enzyme assays and contract screening services.
  • Reaction Biology Corporation: Reaction Biology offers biochemical profiling services and assay reagents covering kinases, ATPases, and other enzyme targets. Closely matches BellBrook's combined products-and-services business model in biochemical HTS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Bellbrook Labs social profiles

Digital presence

Bellbrook Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bellbrook Labs leadership team

Management profile

Number of profiles

Profiles3 records

Bellbrook Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bellbrook Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bellbrook Labs

What does Bellbrook Labs do?

Bellbrook Labs develops, manufactures, and sells biochemical high-throughput screening (HTS) assay kits, recombinant enzymes, assay plates, and small-molecule inhibitors, alongside contract assay development and target profiling services. Its core platforms — Transcreener, AptaFluor, Heliscreener, and Enzolution — enable direct, mix-and-read detection of enzymatic activity for kinase, ATPase, GTPase, phosphodiesterase, glycosyltransferase, exonuclease, methyltransferase, and helicase targets in drug discovery workflows.

Is Bellbrook Labs a public or private company?

Bellbrook Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Bellbrook Labs founded?

Bellbrook Labs was founded in 2005. It employs 11 to 50 people.

Where is Bellbrook Labs based?

Bellbrook Labs is headquartered in Madison, United States, in the North America region.

How does Bellbrook Labs make money?

Three revenue lines are on record. Assay Kits and Reagents are the primary driver. The others are recombinant Enzymes and scientific Services.

Who are Bellbrook Labs's main competitors?

Broad incumbents on record are Bio-Rad Laboratories, Promega Corporation, Thermo Fisher Scientific, Revvity (formerly PerkinElmer Life Sciences) and Cisbio / PerkinElmer HTRF (now Revvity). Enzo Life Sciences is listed as an emerging player. Charles River Laboratories is listed as a regional player. Direct peers are BPS Biosciences, Eurofins DiscoverX and Reaction Biology Corporation.

Does Bellbrook Labs have an API?

No public API is recorded for Bellbrook Labs.

What industry is Bellbrook Labs in?

Bellbrook Labs's product category is Drug Discovery Biochemical Assay Kits. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsSPT Labtech, BellBrook Labs Automate Screening for VPS4B ATPase Inhibitors for Cancer Drug DiscoverySPT Labtech and BellBrook Labs announced a collaboration during the SLAS annual meeting to develop a miniaturized, high-throughput cell-based assay for discovering VPS4B ATPase inhibitors, an important therapeutic target in oncology. The platform combines BellBrook Labs' Transcreener ADP2 fluorescence polarization assay with SPT Labtech's dragonfly automated dispensing system, operating in 384- and 1536-well formats. The partners reported successfully identifying 13 novel VPS4B inhibitors using this combined solution, which they described as a breakthrough that lowers screening barriers while maintaining high data sensitivity.RdworldonlineSLAS 2026 show floor roundup: Partnerships, kits and new categoriesSLAS 2026 in Boston featured multiple partnerships, kit launches, and new technology categories addressing bottlenecks in drug discovery and lab operations. SPT Labtech and BellBrook Labs unveiled a miniaturized cancer screening platform targeting VPS4B ATPase with high hit rates, while Synthace partnered with Charles River Laboratories to integrate DoE software into assay development services. Additional announcements included Omega Bio-tek's automation-ready purification kits, Openshelf's lab inventory automation robot, and Tangible Scientific's compound management platform, along with surveys showing 65% of scientists have repeated experiments due to hard-to-find prior results.The ScientistTargeting RGS14 with AI-Guided Docking and Biochemical AssaysThe webinar will discuss novel AI-driven drug discovery approaches targeting the difficult-to-inhibit RGS14 protein, featuring speakers Robert Lowrey from BellBrook Labs and David Siderovski from the University of North Texas Health. Attendees will learn how to leverage virtual modeling and custom biochemical assays to identify ligands for challenging therapeutic targets. This session is scheduled to take place on February 5, 2026, and will also explore collaboration between academic and industry researchers in drug discovery.PrwebBellBrook Labs to Showcase New HTS Solutions for Methyltransferases and Cancer Immunotherapy Targets at the SLAS 2018 ConferenceBellBrook Labs will showcase its AptaFluor SAH Methyltransferase Assay and Transcreener HTS assays at the SLAS 2018 conference in San Diego. The company will present three posters detailing the new methyltransferase assay and applications for CD39 and kinase assays. The event runs February 5-7.